Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: A review of health economic evaluations

Journal of Chemotherapy

Volumn 22, Issue 2, 2010, Pages 75-82

  Norum, Jan ^a,b,c   Nieder, C ^a,d   Kondo, M ^e  

^a UNIVERSITY OF TROMSØ   (Norway)

^b Regional Health Authority of North Norway   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^d Department of Paediatrics   (Norway)

^e UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Bevacizumab; Health economics; Renal cell carcinoma (RCC); Sorafenib; Sunitinib; Temsirolimus

Indexed keywords

BEVACIZUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH SURVEY; HUMAN; KIDNEY CARCINOMA; METASTASIS; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; REVIEW;

EID: 77951582589     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.2.75     Document Type: Review

References (36)

1. Godley PA, Taylot M. Renal cell carcinoma. Curr Opin Oncol 2001; 13: 199-203.
2. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med 1996; 335: 865-875
3. Mendel DB, Laird AD, Xin X. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial vascular growth factor and platelet-derived growth factor receptors. Determination of a pharmacokinetic /pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337
4. Lang K, Danchenko N, Gondek K, Schwartz B, Thompson D. Burden of illness analysis of renal cell carcinoma. Proc Am Soc Clin Oncol 2006; 24: a14548.
5. Abugaber A, Lang K, Danchenko N, Thompson D, Bhardwaj T, Bjarnason G et al. Cost of illness of renal cell carcinoma in Canada. Proc Am Soc Clin Oncol 2007; 25: a15560.
6. Ljungberg B, Hanbury D, Kuczyk M. Renal cell carcinoma guideline. Eur Urol 2007; 51: 1502-1510
7. th August 2009).
8. Motzer RJ. Hutson TE, Tornczak P, Michaelson MD, Bukowski RM, Rixe O et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124
9. Gonzalez-Perez JG. Developing a scoring system to quality assess economic evaluations. Eur J Health Econ 2002; 3: 131-136
10. Nixon J, Rice S, Drummond M, Boulenger, Ulmann P, de Pouvourville G. Guidelines for the completing the EURONHEED transferability information checklists. Eur J Health Econ 2009; 2: 157-165
11. th of August 2009).
12. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. Br Med J 1996; 313: 275-283
13. Boulenger S, Nixon J, Drummond M, Ulmann P, Rice S, de Pouvourcille G. Can economic evaluations be made more transferable? Eur J Health Econ 2005; 6: 334-346
14. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: Consensus on health economic criteria. Int J Technol Assess Health Care 2005; 21: 240-245
15. Mason JM, Mason AR. The generalisability of pharmacoeconomic studies. Issues and challenges ahead. Pharmacoeconom 2006; 24: 937-945
16. Gao X, Reddy P, Dhanda R, Gondek K, Yeh YC, Stadler WM, et al. Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma. Proc Am Soc Clin Oncol 2006; 24: a4604.
17. Mickisch G, Escudier BJ, Gore ME, Walzer S, Sabaté E, Nuijten M. Costs of managing side effects in the treatment of first line metastatic renal cell carcinoma (mRCC) in Germany, France, and UK. Bevacizumab (BEV) + interferon alpha-2a (IFN) compared with sunitinib. Proc Am Soc Clin Oncol 2008; 26: a5110.
18. st line treatment of metastatic renal cell carcinoma (mRCC). An indirect comparison. Proc Am Soc Clin Oncol 2008; 26: a5048.
19. Jaszewski B, Gao X, Reddy PM, Bhardwaj T, Bjamason G, Finelli A, et al. Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma in Canada. Proc Am Soc Clin Oncol 2007; 25: a5111.
20. Dial E, Fournier A, Moyneur E, Neary MP, Duh MS, Oh WK. Frequency and cost of adverse events in renal cell carcinoma (RCC) patients receiving angiogenesis inhibitor therapies. Proc Am Soc Clin Oncol 2008; 26: a14609.
21. Remák E, Charbonneau C, Négrier S, Kim ST, Motzer RJ. Economic evaluation of sunitinib malat for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 3995-4000.
22. Purmonen T, Martikainen JA, Soini EJO, Karaja V, Vuorinen RL, Kellokumu-Lehtinen PL. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clin Ther 2008; 30: 382-392
23. Négrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med. 1998; 338: 1272-1278
24. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006; 295: 2516-2524
25. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 16-24.
26. Steinbrook R. Saying no isn't NICE - The travails of Britain's National Institute for Health and Clinical Excellence. N Engl J Med 2008; 359: 1977-1981
27. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl. J Med 2007; 356: 125-134
28. Hudes G, Carduccl M, Tomczak P. Temsirolimus, interferon alfa or both for advanced renal cell carcinoma. N Engl J Med 2007; 356: 115-124
29. Motzer RJ. Targeted drugs for metastatic renal cell carcinoma. Lancet 2007; 370: 2071-2073
30. Norwegian directorate of Health. National guidelines for diagnosing, treatment and follow up of patients with renal cell carcinoma (RCC). Norwegian directorate of Health, Oslo, 2007.
31. Nadler EEB, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006; 11: 90-95
32. O'Dowd A. Watchdog set to reject four drugs for kidney cancer on the NHS. Br Med J 2008; 337; a1262.
33. Hoyle M, Green C, Thompson-Coon J, Liu Z, Welch K, Moxham T, et al. Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma. Value Health 2009; Sep 25: Epub ahead of print.
34. Hoyle M, Green C, Thompson-Coon J, Liu Z, Welch K, Moxham T, et al. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma. Value Health 2009; Sep 25: Epub ahead of print.
35. Dial E, Duh M, Fournier A, Antras L, Rodermund D, Neary MP, et al. Cost implications of intravenous bevacizumab treatment in patients with renal cell carcinoma (RCC). A retrospective claims database analysis. Proc Am Soc Clin Oncol 2009; 27: a5112.
36. Duh E, Dial E, Chouein TK, Fournier AA, Antras L, Rodermund D et al. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. Curr Med Res Opin 2009; 25: 2081-2090